WO2025063190A1 - エルゴチオネインを含有する組成物 - Google Patents

エルゴチオネインを含有する組成物 Download PDF

Info

Publication number
WO2025063190A1
WO2025063190A1 PCT/JP2024/033212 JP2024033212W WO2025063190A1 WO 2025063190 A1 WO2025063190 A1 WO 2025063190A1 JP 2024033212 W JP2024033212 W JP 2024033212W WO 2025063190 A1 WO2025063190 A1 WO 2025063190A1
Authority
WO
WIPO (PCT)
Prior art keywords
test
ergothioneine
vitality
composition
anger
Prior art date
Application number
PCT/JP2024/033212
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
聡 松本
Original Assignee
株式会社エル・エスコーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社エル・エスコーポレーション filed Critical 株式会社エル・エスコーポレーション
Priority to JP2025517009A priority Critical patent/JPWO2025063190A1/ja
Publication of WO2025063190A1 publication Critical patent/WO2025063190A1/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Definitions

  • the present invention relates to a composition containing ergothioneine as an active ingredient.
  • Ergothioneine is a rare amino acid derivative and a natural substance with strong antioxidant properties.
  • Patent Document 1 describes a food additive containing L-ergothioneine as an active ingredient for preventing or suppressing depression.
  • Patent Document 2 describes an anti-anxiety composition for humans containing L-ergothioneine as an active ingredient.
  • Patent No. 6086568 International Publication No. 2022/230489
  • Patent Document 1 neither Patent Document 1 nor Patent Document 2 discloses that ergothioneine improves vitality or energy, improves positive feelings toward others, reduces anger, or improves negative feelings toward others.
  • Patent Document 2 also discloses that the functions of the anti-anxiety composition are "to make the subject feel lively" and “to reduce temporary loss of vitality and energy.”
  • this is merely a description of the claims, and does not disclose that ergothioneine actually improves vitality or energy.
  • the object of the present invention is to provide a composition that increases vitality and energy, improves positive feelings toward others, reduces anger, and improves negative feelings toward others.
  • ergothioneine has the functions of increasing vitality and/or energy, increasing friendliness and/or empathy, reducing anger, and reducing hostility and/or irritability towards others.
  • the first invention based on this finding is a composition containing L-ergothioneine as an active ingredient for improving vitality and/or energy, improving friendliness and/or empathy, reducing anger, or reducing hostility and/or irritability towards others.
  • the second invention is a composition containing Pleurotus cornucopiae extract as an active ingredient for improving vitality and/or energy, improving friendliness and/or empathy, reducing anger, or reducing hostility and/or irritability towards others.
  • the third invention is the first or second invention, and when orally ingested by a healthy subject, it improves vitality and/or energy, improves friendliness and/or empathy, reduces anger, or reduces hostility and/or irritability towards others.
  • the fourth invention is the first or second invention, which further reduces morning drowsiness or stomach upset.
  • the fifth invention is the first or second invention, in which the intake amount of ergothioneine is 1 mg to 30 mg per adult per day.
  • the sixth invention is a food composition according to the first or second invention.
  • the seventh invention is a pharmaceutical composition according to the first or second invention.
  • the present invention is a composition containing, as an active ingredient, ergothioneine or Pleurotus cullet extract, which has the function of improving vitality and/or energy, improving friendliness and/or empathy, reducing anger, and reducing hostility and/or irritability towards others.
  • friendliness and empathy include positive feelings towards others.
  • Anger and irritability include negative feelings towards others.
  • 1 is a graph showing the results of the POMS2 test on "vigor-vitality.”
  • 1 is a graph showing the results of the "anger-hostility” test in POMS2.
  • 1 is a graph showing the results of a “friendship” test in POMS2.
  • 1 is a graph showing the test results for "heavy stomach” on the Izumo scale.
  • 1 is a graph showing the test results of "morning sleepiness" in OSA-MA.
  • the present embodiment is a composition (hereinafter sometimes referred to as "the present composition") for improving vitality and/or energy, improving friendliness and/or empathy, reducing anger, or reducing hostility and/or irritability towards others, which contains L-ergothioneine (e.g., Pleurotus ulmoides extract) as an active ingredient.
  • L-ergothioneine e.g., Pleurotus ulmoides extract
  • composition can be orally administered to a person (e.g., a healthy individual) in need of such treatment, and can be used in applications or methods for improving at least one of the following: improving vitality and/or energy, improving friendliness and/or empathy, reducing anger, or reducing hostility and/or irritability towards others.
  • compositions for improving vitality and/or vitality can be labeled with functions such as “feeling energetic,” “being able to move energetically,” “being able to work energetically,” “feeling energetic and lively,” “being in a state full of vitality,” and “full of vitality,” in addition to “improving vitality,” “improving vitality,” and “improving vitality and vitality.”
  • “Friendship” means “close interaction as a friend” and means having positive feelings toward others.
  • the "friendship” factor in POMS (registered trademark) 2 described later represents a state of mind in which one feels trust and consideration for others.
  • questions such as (1) enjoying social interactions, (2) caring about others, (3) feeling sympathy, (4) feeling like one is helpful to others, (5) being able to warm others, and (6) trusting others are included, and of these, (1) to (4) are questions related to empathy.
  • the numerical answer value of at least one of the questions selected from (1) to (4) is improved, and the composition also improves empathy.
  • compositions for improving friendliness and/or empathy can be labeled with functions such as “having positive feelings toward others,” “being able to treat others in a friendly manner,” and “facilitating communication with others.”
  • Anger means "to get angry” or "to be full of energy.”
  • compositions for reducing anger can be labeled with functions such as “less likely to get angry,” “less likely to get angry easily,” and “less likely to become sulky.”
  • Hostility means "a desire to be hostile,” or “feelings of criticism toward another person as an enemy.”
  • Hostility means having negative feelings toward others, and causes “irritation.”
  • compositions for reducing hostility and/or irritation toward others can be labeled with functions such as “less likely to get angry toward others,” “less likely to feel ashamed toward others,” “more likely to become kinder toward others,” and “less likely to feel unpleasant toward others.”
  • Patent Document 1 discloses that ergothioneine reduces morning drowsiness or stomach upset.
  • a composition containing L-ergothioneine e.g., Pleurotus cornucopiae extract
  • This composition is a composition for human use.
  • This composition can also be used in applications or methods for improving at least one of the following by orally ingesting the composition by a person (e.g., a healthy person) who needs to reduce morning drowsiness or stomach upset.
  • L-ergothioneine is a type of amino acid that has the chemical structure of the following formula (1) in a crystalline state.
  • L-ergothioneine may be in the form of a free form or in the form of a salt.
  • the salt of L-ergothioneine may be a salt formed with the carboxyl group in these structures, or may be a salt formed with the trimethylamino group or the amino group.
  • L-ergothioneine may also be a solvate such as a hydrate.
  • the salt of L-ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for food and beverages, and may be an acidic salt or a basic salt.
  • acidic salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate; organic acid salts such as acetate, citrate, maleate, malate, oxalate, lactate, succinate, fumarate, and propionate; and the like.
  • basic salts include alkali metal salts such as sodium salt and potassium salt; and alkaline earth metal salts such as calcium salt and magnesium salt.
  • L-ergothioneine is known to become a tautomer with a thiol structure in solution, and is stable against heat and acid.
  • L-ergothioneine is an antioxidant like ascorbic acid, and cannot be synthesized in the body and must be ingested from the outside. From the standpoint of digestibility, safety, taste, etc., the L-ergothioneine contained in this composition can be extracted and purified from natural products containing L-ergothioneine (mushrooms, sake lees, etc.), or chemically synthesized L-ergothioneine can be used.
  • Mushrooms from which L-ergothioneine can be extracted include Tamogitake (scientific name: Pleurotus cornucopiae var. citrinopileatus), Flammulina velutipes, etc., which belong to the Flammulina genus, Leucopaxillus giganteus, etc., which belong to the Leucopaxillus genus, and Phellinus genus.
  • At least one or more species can be selected from the group consisting of shimeji (Lyophyllum decastes), Rozites caperata (Rozites genus), Pholiota nameko (Pholiota genus), Pleurotus pulmonarius, Pleurotus ostreatus, Pleurotus eryngii (Pleurotus genus), Mycoleptodonoides aitchisonii (Mycoleptodonoides genus), Agrocybe cylindracea (Agrocybe genus), and Grifola gargal (Grifola genus).
  • Tamogitake, Enokitake, Ginkgo biloba, Coprinus comatus, Yamabushitake, Honshimeji, Nameko, Pleurotus oyster, King oyster mushroom, and Bunaharitake are preferred from the standpoint of low side effects and safety when the extract is used over a long period of time, and among these, Tamogitake is also easy to collect domestically.
  • composition when the composition is made into a food composition (including a beverage composition), in addition to L-ergothioneine, it may contain other ingredients commonly used in foods and beverages (nutritional ingredients such as vitamins and minerals, food ingredients, or food additives, etc.).
  • other ingredients include ethanol or water as a solvent, sweeteners, flavorings, seasonings, coloring agents, preservatives, bulking agents, thickening agents, thickening stabilizers, antioxidants, bittering agents, acidulants, emulsifiers, strengthening agents, manufacturing agents, excipients, disintegrants, binders, lubricants, coating agents, and plasticizers.
  • the composition can be a food composition (including a beverage composition) such as a solid, semi-solid or liquid, and can be provided, for example, as confectionery (cookies, jellies, etc.), bread, processed fish products, processed meat products, noodles, soups, sauces, side dishes, beverages (milk drinks, lactic acid bacteria drinks, soft drinks, vegetable drinks, powdered drinks, sports drinks, nutritional drinks, etc.).
  • the composition can also be provided as health foods, functional foods, nutritional supplements, supplements, foods for specified health uses, foods for the sick, combination foods for the sick, or foods for the elderly.
  • the composition can be provided as a drug or quasi-drug.
  • the composition can be ingested in an appropriate manner according to its form. There are no particular limitations on the method of ingestion, so long as the active ingredient contained in the composition can be transferred into the circulating blood.
  • the composition can be in the form of an oral preparation, or a non-oral preparation such as an injection, topical preparation, suppository, or transdermal absorption agent, but is not limited to these.
  • the term "ingestion” is used to include all aspects such as ingestion, taking, or drinking.
  • the composition can be in the form of a solid, liquid, powder, granules, paste, mousse, gel, jelly, tablet, or other form (dosage form).
  • the composition can also be in the form of a packaged bag, container, capsule, or the like.
  • the composition can be used so that the intake amount of L-ergothioneine (intake amount per adult per day) is 1 mg to 30 mg, more preferably 3 mg to 25 mg, and even more preferably 5 mg to 25 mg.
  • the intake amount of L-ergothioneine can be contained per one or a specified number of pieces.
  • the intake amount of L-ergothioneine can be contained in one package or container.
  • the intake amount of L-ergothioneine can be displayed on the package or the like as the recommended daily intake amount.
  • the number of times per day to achieve the daily intake amount may be one or multiple times.
  • the Tamogitake extract can be processed by freeze-drying or spray-drying.
  • the Tamogitake extract can be deodorized and decolorized using a filtration membrane, and the filtrate after the deodorization and decolorization can be powdered by a spray-drying method or the like, and the beverage composition can be made using the powder as a beverage ingredient.
  • Tamogitake extract can be powdered by a spray-drying method or the like, and the powder can be used as a beverage ingredient to make a beverage composition.
  • Tamogitake extract can be prepared by subjecting the broth obtained by boiling Tamogitake to an ion exchange resin, obtaining an eluate of cationic compounds from the ion exchange resin, concentrating the eluate, and passing the concentrated liquid through high-performance liquid chromatography to separate and purify L-ergothioneine.
  • a clinical trial using a food containing ergothioneine derived from Tamogitake mushroom is described, targeting healthy individuals who are not suffering from any disease (those who feel stress on a daily basis and experience physical discomfort (chronic, not corresponding to a disease) such as poor sleep quality and fatigue).
  • the present invention is not limited to this example, as long as it does not go beyond the gist of the invention.
  • the units and measurement methods described in this example are in accordance with JIS standards.
  • test food group a group consuming an ergothioneine-containing food
  • placebo food control food group
  • a screening survey was conducted on 59 individuals, and 52 individuals who met all of the eligibility criteria (1) to (11) and did not meet any of the exclusion criteria (A) to (D) were included as subjects.
  • the subjects were randomly assigned using a permuted block method to avoid bias in the gender ratio and age.
  • the subject backgrounds for each group were 14 men and 12 women in the test food group, and 13 men and 13 women in the control food group. No significant differences were observed between groups in subject background data for height, weight, BMI, systolic blood pressure, diastolic blood pressure, pulse rate, and body temperature.
  • test food and method of taking the test food were of two types, as shown in Table 1, and were managed by distinguishing them with identification codes.
  • the control foods were designed so that they could not be distinguished from the test foods by color, smell, appearance, etc.
  • the test food ingested by the test food group was a beverage containing 5 mg of ergothioneine obtained from Pleurotus ulmoides extract, and the control food ingested by the control food group was a beverage containing 0 mg of ergothioneine.
  • the test foods were prepared by deodorizing and decolorizing Pleurotus ulmoides extract using a filtration membrane, powdering the filtrate after the deodorization and decolorization process by spray drying, and using the powder to produce a beverage.
  • each subject consumed one bottle of the test food per day for 28 days, and then the second test (test at 4 weeks of intake). Then, the subject consumed one bottle of the test food per day for another 28 days, and then the third test (test at 8 weeks of intake). The second test was conducted within 28 days ⁇ 3 days from the date of the first test, and the third test was conducted within 56 days ⁇ 6 days from the date of the first test.
  • the test items conducted by each subject are shown in Table 2.
  • OSA-MA OSA Sleep Assessment Table MA version
  • each subject refrained from excessive eating and drinking the day before, ate a meal after waking up on the day of the test, and underwent a medical interview, physical examination, blood pressure measurement, and blood and urine tests (at screening and 8 weeks after intake).
  • each subject was given a cognitive stress load on the brain by conducting Cognitrax tests (SDC test, Stroop test, shifting attention test, and 4-part sustained processing test) at 0 weeks, 4 weeks, and 8 weeks after intake, and efficacy evaluations (POMS2 and Izumo scale) were conducted immediately after the Cognitrax tests were completed.
  • each subject filled out an OSA-MA questionnaire every morning when they woke up to evaluate the quality of their sleep.
  • POMS2 is a test to evaluate the mood state in a specified time frame (the past week including the day of the test) using seven scales of "anger-hostility”, “confusion-bewilderment”, “depression-depression”, “fatigue-lethargy”, “tension-anxiety”, “vigor-vitality” and “friendship”, and the “TMD score” which comprehensively represents the negative mood state as test items.
  • each subject answered 65 questions at 0 weeks (0w), 4 weeks (4w), and 8 weeks (8w) of intake with five options: “not at all", “a little”, “somewhat", “quite a lot", and "very much".
  • the "Izumo Scale” was administered to evaluate gastrointestinal symptoms.
  • the Izumo Scale is a questionnaire for evaluating gastrointestinal symptoms.
  • the five factors of "heartburn,”"stomachpain,””heavystomach,””constipation,” and “diarrhea” were used as test items to evaluate the decline in QOL due to gastrointestinal symptoms.
  • OSA-MA To measure sleep quality and sleep sensation, the "OSA-MA" was conducted. In the OSA-MA, each subject was asked to answer five factors (sleepiness upon waking, falling asleep and staying asleep, dreaminess, fatigue recovery, and sleep time) as test items for each of the 16 items in the five factors using four options: “(negative evaluation) very”, “(negative evaluation) somewhat”, “(positive evaluation) somewhat”, and “(positive evaluation) very”. The above-mentioned five factors were used as test items in the OSA-MA.
  • Figures 1 to 3 show the analysis results for each of the test items: "Vibrancy-Energy,” “Anger-Hostility,” and “Friendship.”
  • the vertical axis shows the average score for the corresponding test item (amount of change based on week 0 of intake) for the analysis subjects (subjects in each group).
  • the horizontal axis shows the timing of the test (week 0 of intake, week 4 of intake, week 8 of intake).
  • the dashed line shows the analysis results for the test food group
  • the solid line shows the analysis results for the control food group.
  • L-ergothioneine was found to be effective in improving "vitality and energy,” improving “friendship,” and decreasing (or suppressing) "anger-hostility.”
  • Compositions containing L-ergothioneine as an active ingredient are useful as vitality enhancers, vitality enhancers (motivation enhancers), vitality and energy enhancers, friendliness enhancers, empathy enhancers, friendliness and empathy enhancers, hostility reducers, irritability reducers, hostility and irritability reducers, and anger reducers. They are particularly useful for healthy individuals.
  • the correlation coefficient for "vigor-vitality” with “depression-depression” was -0.23 (weak negative correlation)
  • the correlation coefficient for "tension-anxiety” was -0.35 (weak negative correlation)
  • the correlation coefficient for "fatigue-lethargy” was -0.31 (weak negative correlation).
  • the correlation coefficient for "friendliness” with “depression-depression” was -0.14 (no correlation)
  • the correlation coefficient for "tension-anxiety” was -0.09 (no correlation)
  • the correlation coefficient for "fatigue-lethargy” was -0.26 (weak negative correlation).
  • the Izumo Scale was analyzed for each of the five test items for the above-mentioned five factors. The analysis results are shown in Table 5 (test food group) and Table 6 (control food group). No significant differences were observed between groups at week 0 of intake for any of the test items.
  • FIG 4 shows the analysis results for the test items for "heavy stomach”.
  • the vertical axis shows the average score for the corresponding test item (amount of change based on 0 weeks of ingestion) for the analysis subjects.
  • the horizontal axis shows the timing of the test (0 weeks of ingestion, 4 weeks of ingestion, 8 weeks of ingestion).
  • the dashed line shows the analysis results for the test food group
  • the solid line shows the analysis results for the control food group.
  • the change in the test item at 4 weeks of ingestion and 0 weeks of ingestion was p ⁇ 0.05, confirming a significant difference within the group.
  • L-ergothioneine was found to be effective in improving (reducing) "heavy stomach feeling."
  • Compositions containing L-ergothioneine as an active ingredient are useful as agents for improving (reducing) heavy stomach feeling. They are particularly useful for healthy individuals.
  • OSA-MA was analyzed for each of the five test items for the above-mentioned factors. The analysis results are shown in Table 7 (test food group) and Table 8 (control food group). No significant differences were observed between groups at week 0 of intake for any of the test items. vinegar.
  • the test item "sleepiness upon waking" had a p ⁇ 0.05 result for the actual measured value at 4 weeks of ingestion, confirming a significant difference between the test food group and the control food group.
  • Figure 5 shows the analysis results for the test item "sleepiness upon waking.”
  • the vertical axis shows the average score for the corresponding test item (actual measured value at each test timing) for the analysis subjects.
  • the horizontal axis shows the test timing (0 weeks of ingestion, 4 weeks of ingestion, 8 weeks of ingestion).
  • the dashed line shows the analysis results for the test food group
  • the solid line shows the analysis results for the control food group.
  • p ⁇ 0.05 was obtained before and after 8 weeks of ingestion and 0 weeks of ingestion for the test food group, confirming a significant difference within the group.
  • L-ergothioneine has been found to be effective in improving (reducing) "morning drowsiness.”
  • Compositions containing L-ergothioneine as an active ingredient are useful as agents for improving (reducing) morning drowsiness. They are particularly useful for healthy individuals.
  • the present invention can be applied to compositions containing ergothioneine as an active ingredient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Anesthesiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PCT/JP2024/033212 2023-09-19 2024-09-18 エルゴチオネインを含有する組成物 WO2025063190A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025517009A JPWO2025063190A1 (enrdf_load_stackoverflow) 2023-09-19 2024-09-18

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023150777 2023-09-19
JP2023-150777 2023-09-19

Publications (1)

Publication Number Publication Date
WO2025063190A1 true WO2025063190A1 (ja) 2025-03-27

Family

ID=95073050

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2024/033212 WO2025063190A1 (ja) 2023-09-19 2024-09-18 エルゴチオネインを含有する組成物

Country Status (2)

Country Link
JP (1) JPWO2025063190A1 (enrdf_load_stackoverflow)
WO (1) WO2025063190A1 (enrdf_load_stackoverflow)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016116531A (ja) * 2013-02-28 2016-06-30 株式会社エル・エスコーポレーション 食品添加剤及び食品
CN109938332A (zh) * 2019-03-01 2019-06-28 华熙生物科技股份有限公司 一种含麦角硫因的猴头菌保健品制剂及其制备方法
WO2021085062A1 (ja) * 2019-10-28 2021-05-06 サントリーホールディングス株式会社 エルゴチオネイン又はその塩を含有する睡眠改善用組成物
WO2022230489A1 (ja) * 2021-04-26 2022-11-03 サントリーホールディングス株式会社 抗不安用組成物
WO2024038821A1 (ja) * 2022-08-17 2024-02-22 サントリーホールディングス株式会社 フレイル予防又は改善用組成物、及び、加齢に伴う身体活動能力低下を抑制又は改善するための組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016116531A (ja) * 2013-02-28 2016-06-30 株式会社エル・エスコーポレーション 食品添加剤及び食品
CN109938332A (zh) * 2019-03-01 2019-06-28 华熙生物科技股份有限公司 一种含麦角硫因的猴头菌保健品制剂及其制备方法
WO2021085062A1 (ja) * 2019-10-28 2021-05-06 サントリーホールディングス株式会社 エルゴチオネイン又はその塩を含有する睡眠改善用組成物
WO2022230489A1 (ja) * 2021-04-26 2022-11-03 サントリーホールディングス株式会社 抗不安用組成物
WO2024038821A1 (ja) * 2022-08-17 2024-02-22 サントリーホールディングス株式会社 フレイル予防又は改善用組成物、及び、加齢に伴う身体活動能力低下を抑制又は改善するための組成物

Also Published As

Publication number Publication date
JPWO2025063190A1 (enrdf_load_stackoverflow) 2025-03-27

Similar Documents

Publication Publication Date Title
Shannon et al. Dietary nitrate and population health: a narrative review of the translational potential of existing laboratory studies
TWI583390B (zh) 富含鞣花單寧之萃取物組成物
JP7281031B2 (ja) 加齢に伴う持続的注意力低下の改善用の組成物
EP3133941B1 (en) Composition for using cinnamaldehyde and zinc for weight management
JP2021176333A (ja) 桂皮アルデヒド及び亜鉛を含む組成物並びにかかる組成物の使用方法
JP7602812B2 (ja) Ｑｏｌ改善剤
JP2025069354A (ja) 認知機能の低下抑制および／または改善用組成物
JP2014237715A (ja) アルコール性疲労改善剤
CN109069532A (zh) 含铬组合物用于改善健康和健身
JP6782381B1 (ja) 脳機能改善用食品組成物、脳機能改善剤、脳由来神経栄養因子増加用食品組成物、ストレスホルモン分泌抑制用食品組成物、脳由来神経栄養因子増加剤及びストレスホルモン分泌抑制剤
CN106470691B (zh) 包含肉桂醛和锌的组合物及此类组合物的使用方法
WO2025063190A1 (ja) エルゴチオネインを含有する組成物
JP2008545766A (ja) （−）−エピガロカテキンガレートの新規使用
WO2005087022A1 (ja) 抗ストレス作用を有する食品組成物
WO2021239823A1 (en) Preventing or treating nitric oxide deficiency related conditions
JP2006197911A (ja) 蜂の子利用の健康食品。
CN115944656A (zh) 认知功能改善剂、认知功能维持剂、海马体功能改善剂和海马体功能维持剂
CN101370555A (zh) (-)-表没食子儿茶素没食子酸酯的新型用途
JP2008044885A (ja) 疲労予防用内服用組成物及び疲労予防用内服用製剤
JP6533784B2 (ja) 眼の疲れ改善剤
EP4137206A1 (en) Agent for improving quality of sleep
JP5876214B2 (ja) 乳酸菌共生培養抽出液の製造方法
JP7345771B2 (ja) 糖尿病によって誘発される知覚過敏または知覚異常の予防又は治療用組成物
JP6881984B2 (ja) 過食抑制剤
HK40083684A (en) Agent for improving quality of sleep

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2025517009

Country of ref document: JP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24868267

Country of ref document: EP

Kind code of ref document: A1